Caporali, Roberto
Kadakia, Aditi
Howell, Oliver
Patel, Jayesh
Milligan, Jack
Strengholt, Sander
Barlow, Sophie
Taylor, Peter C.
Funding for this research was provided by:
AbbVie
Article History
Received: 22 April 2024
Accepted: 13 July 2024
First Online: 7 August 2024
Declarations
:
: Roberto Caporali has received speaker and/or consultant fees from AbbVie, Accord, Celltrion, Eli Lilly, Fresenius, Galapagos, Janssen, MSD, Novartis, Pfizer Inc, and UCB. Peter C. Taylor has received grant and/or research support from Galapagos and has acted as a consultant for AbbVie, Biogen, Eli Lilly, Fresenius, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer Inc, Sanofi, and UCB. Jayesh Patel, Aditi Kadakia, and Sander Strengholt are employees of AbbVie Inc and may own stock. Oliver Howell, Jack Milligan, and Sophie Barlow are employees of Adelphi Real World, who acted as consultants to AbbVie for this analysis and have no other conflicts of interest.
: Using a check box, patients provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. Data were collected in such a way that patients and physicians could not be identified directly; all data were aggregated and de-identified before receipt. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines, and therefore it does not require ethics committee approval. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.